Dr. Roopal Thakkar, AbbVie’s Chief Medical Officer for Global Therapeutics, underscored the significance of NX-13, hailing it as a “differentiated, first-in-class, oral asset” with the power to positively impact the lives of those afflicted by ulcerative colitis and Crohn’s disease.
Strategic Vision and Industry Leadership
With the transaction slated for closure in the second quarter of 2024, pending regulatory approval and fulfillment of closing conditions, AbbVie emerges as a pivotal player in steering NX-13 towards its full potential. Gregory Oakes, CEO of Landos Biopharma, expressed confidence in AbbVie’s prowess, citing their expertise and leadership in therapeutic areas as instrumental in propelling NX-13 forward.
AbbVie’s pursuit of transformative acquisitions has been evident in its recent endeavors. Earlier announcements included the acquisition of cancer drugmaker ImmunoGen Inc. for a staggering $10.1 billion and a deal with Cerevel Therapeutics valued at approximately $8.7 billion.
AbbVie to buy Landos Biopharma for $212M : Legal Titans Pave the Way
Behind the scenes, legal heavyweights orchestrated the intricate details of the acquisition. The Paul Weiss team, led by corporate partners Benjamin Goodchild and Krishna Veeraraghavan, spearheaded AbbVie’s representation. Meanwhile, Cooley LLP, under the guidance of corporate partners Kevin Cooper and Eric Blanchard, navigated Landos Biopharma through the complexities of the deal.
